Anlon Healthcare IPO

7.04x

subscribed

Anlon Healthcare IPO

Pharmaceuticals & Drugs
listed
₹14,104Min. investment
  1. Pre-apply
    25 Aug
  2. Bid start
    26 Aug
  3. Bid end
    29 Aug
  4. Allotment
    1 Sep
  5. Release of funds
    2 Sep
  6. Demat transfer
    2 Sep
  7. Listing
    3 Sep

About Anlon Healthcare Limited

SectorPharmaceuticals & Drugs
Price range₹86.00 – ₹91.00
IPO type
Regular
Lot size164 shares
Issue size₹121Cr
Red Herring Prospectus
Read
Market Cap
₹483.68CrLower than sector avg
RevenueApr 2024 - Mar 2025
₹120.29CrLower than sector avg
Growth rate3Y CAGR
2.14%

Anlon Healthcare Limited IPO Overview

Anlon Healthcare Limited IPO date

Anlon Healthcare Limited IPO will open for subscription on August 26, 2025, and the closing date for the IPO is August 29, 2025. After this, investors are expected to be updated about the allotment status on September 01, 2025.

Investors who have been allotted shares can expect them to be credited to their demat account on September 02, 2025. The shares will be listed on the NSE and the BSE on Wednesday, September 03, 2025.

Anlon Healthcare Limited IPO price band

The IPO includes a fresh issue of shares and an offer for sale. The IPO price band has been set between ₹86 to ₹91 per share. Interested investors can choose a price within this band to apply for the IPO. The IPO is a book-building issue, comprising a fresh issue of ₹121.03 crore only.

Anlon Healthcare Limited's IPO listing price will be determined on September 3, 2025. The listing price is the price at which a company’s shares debut on the stock exchanges.

Anlon Healthcare Limited IPO lot size

Anlon Healthcare Limited IPO details have been declared. The minimum lot size for an application is 164 shares, and the investor would have to apply for a minimum of 1 lot. Meanwhile, the IPO issue size is approximately ₹ 121.03 crore.

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Compare

Companies in this sector
Sun Pharmaceutical Industries LtdSun Pharmaceutical Industries Ltd
Divi's Laboratories LtdDivi's Laboratories Ltd
Cipla LtdCipla Ltd
Revenue
Higher revenue means strong sales and good market demand
This IPO
₹120.29Cr
This sector
₹1,331.47Cr
Compare with companies
PAT
Higher PAT means strong profitability and efficient cost management
This IPO
₹20.52Cr
This sector
₹193.4Cr
Compare with companies
Market cap
Higher market cap means strong confidence but may suggest overvaluation
This IPO
₹483.68Cr
This sector
₹10,914.84Cr
Compare with companies
P/E ratio
Lower ratio usually means stock is undervalued
This IPO
14.26
This sector
60.87
Compare with companies
D/E ratio
Lower ratio usually means fewer liabilities
This IPO
0.73
This sector
0.43
Compare with companies

Objectives

Working capital requirements
35.65%
General corporate purposes
35.00%
Capital expenditure
25.38%
Repayment of loans
4.13%

Strength and Weakness

Diversified product portfolio

Anlon Healthcare boasts a strong portfolio of 65 commercialised products and 28 products at the pilot stage as of March 2025. The product mix covers pharmaceutical intermediates, APIs, nutraceuticals, personal care, and veterinary APIs, serving a wide range of end-user industries. This diversity supports scale and market resilience in domestic and export markets, with 142 products in various development stages.

High capacity utilisation

Operating from a single zero-liquid-discharge facility in Rajkot with 400 MTPA installed capacity, Anlon Healthcare achieved 84.41% capacity utilisation in FY25. Plans are underway to increase installed capacity to 1,100 MTPA with a new plant, aiming to capitalise on demand growth and expand market share.

Leadership in niche APIs

Anlon is among the few Indian manufacturers of loxoprofen sodium dihydrate, holding regulatory DMF approvals in Brazil, China, and Japan, and has filed 21 DMFs globally. This positions the company for robust international growth and regulatory credibility.

High standards in quality assurance

Anlon’s manufacturing is ISO 9001:2015, GMP, and WHO-GMP certified. The facility is regularly audited by over 33 customers and regulatory authorities, evidencing strict global quality adherence and robust compliance systems. Complementing its quality efforts, Anlon Healthcare’s operations are technology-driven and sustainability-oriented, committed to environmental stewardship, and operating a zero liquid discharge (ZLD) manufacturing facility.

About Anlon Healthcare Limited

Anlon Healthcare is a chemical manufacturing company engaged in the manufacturing of pharma intermediates and active pharmaceutical ingredients (APIs). Its products serve as raw materials and key starting materials for manufacturing APIs and pharmaceutical formulations, including tablets, capsules, ointments, and syrups, as well as ingredients for nutraceuticals, personal care products, and animal health products. The company operates from a single manufacturing facility located in Rajkot, Gujarat. The facility comprises two separate manufacturing blocks for pharmaceutical intermediates and APIs with an aggregate installed production capacity of 400 MTPA, along with four in-house laboratories and storage facilities.
The company’s product portfolio consists of 65 commercialised products, 28 products at the pilot stage, and 49 products at the laboratory testing/laboratory scale stage, totalling 142 products across various categories. This represents substantial growth from 83 total products in FY23 to 142 products in FY25. Its commercialised products include 22 pharmaceutical intermediates, 18 APIs, 20 nutraceutical APIs, 3 personal care products, and 2 animal health products. Key products span across therapeutic categories, including anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, and nutritional supplements.
The company has received Drug Master File (DMF) approvals from major regulatory authorities, including the Brazilian Health Regulatory Agency (ANVISA) for loxoprofen sodium dihydrate, the National Medical Products Administration of China (NMPA) for loxoprofen sodium dihydrate, and the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) for loxoprofen sodium dihydrate and loxoprofen acid. It has filed 21 DMFs with regulatory authorities across the European Union, Russia, Japan, South Korea, Iran, Jordan, and Pakistan.
The company supplies products to both domestic and overseas markets, serving customers in over 15 countries. Their manufacturing facility has been audited and approved by 33 customers and their respective regulatory authorities. It manufactured and sold 338 MT of APIs and pharma intermediates in FY25 to 38 customers, compared to 153 MT to 39 customers in FY24 and 316 MT to 48 customers in FY23. Revenue concentration among the top 10 customers remains high at approximately 77-78% across the 3 fiscal years.
The Indian pharmaceutical industry is ranked the 3rd largest globally by volume and is expected to grow at a CAGR of 10% during FY24-30, reaching INR 7,30,000 crore by FY30. The API market, representing approximately 35% of the pharmaceutical market, is expected to grow at a CAGR of 13.7%, while the nutraceutical market is projected to grow at a 10-12% CAGR over the next few years. Key demand drivers include an ageing population expected to touch 17.3 crore by 2026, higher per capita income improving affordability, increasing penetration of health insurance through Ayushman Bharat, and a sharp rise in lifestyle-related diseases such as diabetes and cardiovascular ailments.
These industry dynamics present strong tailwinds for Anlon Healthcare. The company stands to gain from India’s growing role in global supply chains amid the “China+1” diversification strategy adopted by global pharma players, which is driving sourcing away from China toward Indian manufacturers. Further, rising demand in high-growth categories such as nutraceuticals (10–12% CAGR), veterinary APIs, and personal care APIs provides opportunities for diversification.
Now, Anlon Healthcare Ltd is launching its initial public offering (IPO), which consists of a fresh issue worth up to ₹121.03 crore. The total issue size of the IPO is ₹121.03 crore. Its shares will be listed on the NSE and BSE.

IPO Subscription Status

Date
QIB
NII
Retail
Total
26-Aug-25
0.73 times (X)
0.66 times (X)
9.11 times (X)
1.7 times (X)
28-Aug-25
0.73X
2.02X
22.4X
3.31X
29-Aug-25
0.82X
10.23X
46.63X
7.04X

Latest News on IPO

news logo
Anlon Healthcare has filed preliminary papers with the capital markets regulator SEBI to raise funds via initial public offering. The IPO will entirely be a fresh issue of 1.4 crore equity shares by the company, with no offer-for-sale component, as per the draft papers filed on October 9. Promoters own 70.26 percent stake in the company.
news logo
Anlon Healthcare, a Rajkot-based pharmaceutical manufacturer, has refiled its IPO draft papers with SEBI, seeking to raise funds through a fresh issue of 1.4 crore equity shares, with no offer-for-sale component, to expand its manufacturing facility, repay debt, and meet working capital requirements. Anlon Healthcare, a Rajkot-based pharmaceutical manufacturer.
news logo
Anlon Healthcare IPO seeks to raise ₹121.03 crore by offering 1.33 crore new equity shares. There is no offer for sale component.

3 min read

news logo
Anlon Healthcare IPO: The initial public offering aims to raise ₹121.03 crore by issuing 1.33 crore new shares. There is no offer for sale (OFS) component.

2 min read

news logo
Anlon Healthcare IPO seeks to raise ₹121.03 crore via fresh issuance of 1,33,00,000 shares. There is no offer-for-sale component.

3 min read

news logo
Anlon Healthcare IPO: The initial share sale, which seeks to raise ₹121.03 crore, is a fresh issuance of 1.33 crore shares. There is no offer for sale component. Hence, the funds raised will go to the company.

3 min read

news logo
Anlon Healthcare IPO allotment: The initial share sale, which sought to raise ₹121.03 crore, was a fresh issue of up to 1.33 crore equity shares. There was no offer for sale (OFS) component.

3 min read

Frequently asked questions

How to invest in the IPO?

Investors can apply for the IPO through their Demat account via the stock exchange or through their broker.

What is the issue size of Anlon Healthcare IPO ?

The issue size of the Anlon Healthcare IPO is 121 Cr.

What is 'pre-apply' for Anlon Healthcare IPO ?

Pre-applying for an IPO allows you to submit your application before the official subscription period begins.

Which exchanges will Anlon Healthcare IPO shares list on?

The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.